A Study to Investigate HLA-G Targeted Exosome (SOB100) in Healthy Subjects

NCT07219940 ↗

Phase 1 Recruiting 15 enrolled Shine-On Biomedical Co., Ltd.

NaSingle-groupOpen-labelTreatment

Summary

The investigational drug, SOB100, is an HLA-G targeted exosome equipped with a nanobody namely anti-HLA-G VHH on the exosome membrane. This is a Phase I dose escalation study to exam the tolerability, safety, and pharmacokinetics in healthy subjects.

Timeline

Start: 2025-12-01
Primary completion: 2026-12
Completion: 2027-03

Publications

Yang KJ, Yu NY, Goldwater R, Chang CH, Liu CM, Kan KW, Chen YW, Cho DY, Melville D, Ho JH. A study to investigate HLA-G targeted exosome (SOB100) in healthy subjects. Nanomedicine (Lond). 2026 Jun;21(11):1565-1569. doi: 10.1080/17435889.2026.2668706. Epub 2026 May 5.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	SOB100	Unknown	—	—

Indications

No indication recorded.